Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mental strategy training may quiet a key brain region linked to Alzheimer's risk

NCT ID NCT07718945

Symptom relief Sponsor: Jessica Peter Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether mental strategy training can reduce overactivity in the hippocampus — a brain region that often becomes hyperactive in early Alzheimer's — and improve memory in people with mild cognitive impairment (MCI). Participants aged 60–80 with MCI will practice four mental strategies (imagination, bodily perception, active thinking, and visual perception) during 2, 4, or 6 group sessions. Brain activity and memory are measured with fMRI and a pattern separation task before, during, and after training.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mental strategy training (imagination, bodily perception, active thinking, visual perception)
What this could lead to
If it works, this could point toward a non-drug way to slow memory decline in people at high risk for Alzheimer's disease.
What could go wrong
This is a small, early-stage trial with only 55 participants. The training may not reduce brain activity enough to improve memory, and benefits might not last.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Feb 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosis of Mild Cognitive Impairment * between 60 - 80 years of age * fluent in German * normal or corrected-to-normal vision * normal or corrected-to-normal hearing Exclusion Criteria: * any history of seizures * current psychotropic medication * other severe neurological or psychiatric disease * current or lifetime drug or alcohol abuse * severe brain damage other than atrophy in the hippocampus or the medial temporal lobe * claustrophobia * magnetisable implants (e.g., cardiac pacemakers, brain stimulator)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amnestic disorder Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment Mild cognitive impairment (MCI) amnestic

Contacts and locations

Locations

  • Universitäre Psychiatrische Dienste Bern

    Bern, Canton of Bern, 3000, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.